Company: LENZ
Filing Date: 2025-05-07
Form Type: 10-Q
Source: 0001815776-25-000032
Chunk: 347

Company: LENZ Therapeutics, Inc.
Filing Date: 2025-05-07
Form: 10-Q
Item: Part I, Item 8
Chunk 347
---
(2)25,222 Totals$193,431 $145 $(22)$193,554 

13

December 31, 2024Amortized CostGrossUnrealizedGainsGrossUnrealizedLossesEstimated FairValueCash equivalents:Money market funds$17,693 $— $— $17,693 U.S. government securities999 — — 999 U.S. treasury securities997 — — 997 Marketable securities:Commercial paper$58,798 $56 $(31)$58,823 U.S. treasury securities46,231 80 (2)46,309 Corporate debt securities43,634 49 (14)43,669 U.S. government agency securities40,013 60 (2)40,071 Totals$208,365 $245 $(49)$208,561 The following table presents available-for-sale securities by contractual maturity date as of March 31, 2025 (in thousands):March 31, 2025Amortized CostEstimated Fair ValueDue in one year or less$155,391 $155,475 Due after one year15,421 15,459 Total$170,812 $170,934 As of March 31, 2025, twenty-four of the Company's marketable securities with a fair market value of $30.5 million were in an immaterial aggregate gross unrealized loss position; these twenty-four marketable securities have all been in a gross unrealized loss position for less than one year. Based on a review of these marketable securities, the Company believes none of the unrealized loss is the result of a credit loss as of March 31, 2025, because the Company does not intend to sell these securities, and it is not more-likely-than-not that the Company will be required to sell these securities before the recovery of their amortized cost basis. Refer to Note 2 for further discussion on the Company's evaluation of unrealized losses on available-for-sale securities. Accrued interest receivable on marketable securities was $1.1 million at both March 31, 2025 and December 31, 2024, and was recorded within prepaid expenses and other current assets in the condensed consolidated balance sheets. We have not written off any accrued interest receivables for the three months ended March 31, 2025 and 202